Taiwan possesses strong biotechtalent and R&D base. AsPhrMApostedin2017, Taiwan ranked 3rdamong 21 emerging countries for its biotech efforts, in particular in the fields of basic infrastructure, practical research and copyright protection.
For raisingthe value of theinnovative research discoveries, the BioMed Commercialization Center (Drug Division, BMCC|Drug) was set up by Taiwan governmentwith the mission to optimize drug commercialization processes for academicand industry clients in Taiwan. BioAsia Taiwan will be one of the largest annual biotech events in Asia, BMCC|Drug is delighted to bring these Taiwan Bio-Innotechs to the participants, the professionals from all over the world,to seekcollaboration, licensing and investmentopportunities.
[Organizer] BioMed Commercialization Center (Drug Division, BMCC|Drug)
[Date] July 25th(Thu), 2019
[Venue] R402a, 4F, Taipei Nangang Exhibition Center, Hall 1 (TNEC1)
(No.1, Jingmao 2nd Rd., Nangang District, Taiepi, Taiwan)
[Registration] Registration is free of charge, however, the organizer reserves the right to change the event program and decide upon admitting the participants.
Please register by JULY 23th via the following link: registration
|
Time |
Topic |
Presenter |
|---|---|---|
|
13:00-13:30 |
Registration |
|
|
13:30-13:40 |
Opening Remarks |
Chi-Feng Chang, Vice President, Development Center for Biotechnology |
|
13:40-13:55 |
Development of an Autologous Hinge as Universal Ab Lock to Enhance Antibody Drug Selectivityand Safety Humanized Bispecific Antibodies that Link PEGylated Nanoparticles with Tumors for Therapy or Imaging |
Tian-Lu Cheng, Professor, KaohsiungMedical University |
|
13:55-14:10 |
Development of WYC-0209-241 as GSTO Inhibitor for Cancer Therapy |
Yang-Chang Wu, Chair Professor, China Medical University |
|
14:10-14:25 |
The Novel αIIbβ3Antagonist TMV-7 and Its Derivative RR Prevent Thrombosis without the Risk of Bleeding |
Tur-Fu Huang, Emeritus Professor, Mackay Medical College |
|
14:25-14:40 |
High Yielding CHO Cell Expression System |
Hsin-LinLu, Research Fellow, Development Center for Biotechnology |
|
14:40-14:55 |
Quantity and Quality Controlled Bioprocess of Chimeric Antigen Receptor (CAR)-T Cells |
Hsin-LinLu, Research Fellow, Development Center for Biotechnology |
|
14:55-15:10 |
Adenosine Augmentation Compounds for the Treatment of Neurodegenerative Diseases |
Yijuang Chern, Distinguished Research Fellow, Academia Sinica |
|
15:10-15:20 |
Break |
|
|
15:20-15:35 |
A New Combinational Treatment Method of TMG/DMG with Ketamine for Psychiatric Disorders |
Hwei-Hsien Chen, Investigator, National Health Research Institutes |
|
15:35-15:50 |
Highly Selective HDAC6 Inhibitor MPT0G211, in Preclinical Studies, Available for Licensingor Co-development |
Shiow-Lin Pan, Professor, Taipei Medical University |
|
15:50-16:05 |
Development of Antibody Drug AP001 against a Novel Tumor Marker Protein AP for Human Cancer Treatment |
Wei-Chun HuangFu, Assistant Professor, Taipei Medical University |
|
16:05-16:20 |
Selective Topo-II Chemotherapeutics |
Tsai-Kun Li, Professor, National Taiwan University |
|
16:20-16:35 |
Customizable Particles to Enhance the Immunogenicity of Peptide-based T Cell Vaccines |
Che-Ming Hu, Assistant Research Fellow, Academia Sinica |
|
16:35-16:50 |
Development of Anti-lung Cancer Peptide Drug |
Jinghua Tsai Chang, Assistant Professor, Chung Shan Medical University |
|
16:50-17:00 |
Closing |
|